Featured Article

PCSK9 Inhibition: Benefits Outweigh Risks in Patients With Diabetes

PCSK9 Inhibition: Benefits Outweigh Risks in Patients With Diabetes

Statin therapy is the first line of defense against high LDL-C and the risk for atherosclerotic cardiovascular disease, the leading cause of morbidity and mortality in individuals with diabetes.

Latest Features

PCSK9 Inhibition: Benefits Outweigh Risks in Patients With Diabetes

PCSK9 Inhibition: Benefits Outweigh Risks in Patients With Diabetes

Statin therapy is the first line of defense against high LDL-C and the risk for atherosclerotic cardiovascular disease, the leading cause of morbidity and mortality in individuals with diabetes.

Nutraceuticals May Benefit Patients Who Are Statin Intolerant

Nutraceuticals May Benefit Patients Who Are Statin Intolerant

Nutraceuticals may offer a solution to patients who cannot tolerate statins because of severe muscle pain.

Breathing New Life Into COPD and Asthma Therapy With Statins

Breathing New Life Into COPD and Asthma Therapy With Statins

Statins have anti-inflammatory and anti-oxidative effects, which could reduce exacerbations of both asthma and chronic obstructive pulmonary disease.

FOURIER Trial Data Questions: Are PCSK9 Inhibitors The Right Choice?

FOURIER Trial Data Questions: Are PCSK9 Inhibitors The Right Choice?

Results of the FOURIER trial, presented at the 2017 ACC Scientific Sessions, raise questions about the efficacy of PCSK9 inhibitors as long-term therapy for patients with atherosclerotic CVD.

PCSK9 Inhibitor Alirocumab Associated With 75% Reduction in Apheresis

PCSK9 Inhibitor Alirocumab Associated With 75% Reduction in Apheresis

Among patients with heterozygous familial hypercholesterolemia, alirocumab was associated with a 75% reduction in lipoprotein apheresis compared with placebo.

Statins Limit Vaccine Efficacy of Influenza Strain

Statins Limit Vaccine Efficacy of Influenza Strain

Statin use modified vaccine effectiveness and influenza risk for A(H3N2) infection but not for A(H1N1).

Higher Vitamin D Levels May Related to Higher Total Cholesterol, HDL-C

Higher Vitamin D Levels May Related to Higher Total Cholesterol, HDL-C

Vitamin D may influence cardiovascular disease risk via its effect on lipid levels.

Considering Cardiovascular Risks of Antidiabetic Drugs

Considering Cardiovascular Risks of Antidiabetic Drugs

A review of current antidiabetic drug treatments available and their individual cardiovascular risk profiles.

PCSK9 Inhibitors: Breakthrough in LDL-C Reduction, But Comes at a Cost

PCSK9 Inhibitors: Breakthrough in LDL-C Reduction, But Comes at a Cost

PCSK9 inhibitors may offer hope to patients with familial hypercholesterolemia who cannot tolerate or achieve goal LDL-C levels with statins.

LATEST NEWS

Adherence and Intensity of Lipid-Lowering Therapy Influence CV Risk

Adherence and Intensity of Lipid-Lowering Therapy Influence CV Risk

Adherent patients receiving high-intensity statin and/or ezetimibe therapy have the lowest cardiovascular risk.

Should Guidelines Use Higher Risk Thresholds When Recommending Statins for Primary CVD Prevention?

Should Guidelines Use Higher Risk Thresholds When Recommending Statins for Primary CVD Prevention?

Guidelines should incorporate using higher 10-year risk thresholds when recommending statins for the purpose of primary CVD prevention.

AHA Scientific Statement: Low Risk of Side Effects With Statins

AHA Scientific Statement: Low Risk of Side Effects With Statins

Statins are associated with a low risk for side effects, according to a scientific statement from the American Heart Association.

Long-Term Clinical Outcomes of Statin Therapy Post-PCI in Absence of Dyslipidemia

Long-Term Clinical Outcomes of Statin Therapy Post-PCI in Absence of Dyslipidemia

A positive relationship was found between statin use and MACE-free survival after AMI regardless of the presence or absence of dyslipidemia.

Statin Use May Improve Bone Microstructure in Women With Osteoporosis

Statin Use May Improve Bone Microstructure in Women With Osteoporosis

Statin use is associated with better cortical bone characteristics in older women with osteoporosis, but results are dependent upon the potency of the statins.

Coronary Artery Calcium Associated With ASCVD Events in Familial Hypercholesterolemia

Coronary Artery Calcium Associated With ASCVD Events in Familial Hypercholesterolemia

CAC was found to be independently associated with ASCVD events in familiar hypercholesterolemia treated with standard lipid lowering therapy.

Elevated Triglyceride Levels Affect Glycemic Control in Type 2 Diabetes

Elevated Triglyceride Levels Affect Glycemic Control in Type 2 Diabetes

Reducing triglyceride levels in patients with type 2 diabetes may help them attain more optimal glycemic control.

Linear Association Between Plasma Lipoprotein(a) and Calcific Aortic Valve Stenosis Progression

Linear Association Between Plasma Lipoprotein(a) and Calcific Aortic Valve Stenosis Progression

Lipoprotein(a) levels should be measured in mild to moderate calcific aortic valve stenosis to improve patient risk stratification.

Hyperlipidemia Screening Rates Low Among Patients With Rheumatoid Arthritis

Hyperlipidemia Screening Rates Low Among Patients With Rheumatoid Arthritis

Primary lipid screening rates were suboptimal among patients with rheumatoid arthritis.

ACC Releases Consensus Decision Pathway for CVD Risk Reduction in T2D and ASCVD

ACC Releases Consensus Decision Pathway for CVD Risk Reduction in T2D and ASCVD

The American College of Cardiology published an expert consensus statement regarding decision considerations for novel cardiovascular risk reduction therapies in patients with type 2 diabetes and atherosclerotic cardiovascular disease.

Sign Up for Free e-Newsletters